View More Recent Stories
-
TD Cowen Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird
-
Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
-
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovance Biotherapeutics (IOVA) Submits Marketing Authorization Application to EMA for Lifileucel
-
Iovance Biotherapeutics (IOVA) Submits MAA to EMA for Lifileucel in Advanced Melanoma

